EUVIMEDEUVIMED entdecken
Crossref

Chromone–deferiprone hybrids as novel MAO-B inhibitors and iron chelators for the treatment of Alzheimer's disease

Da-Jiang Zou, Ren-Zheng Liu, Yang-Jing Lv, Jia-Nan Guo, Miao-Liang Fan, Chang-Jun Zhang, Yuan-Yuan Xie iD

Organic & Biomolecular Chemistry · 2024

DOI: 10.1039/d4ob00919c ↗

Kurz gefasst

Fachartikel in der Zeitschrift Organic & Biomolecular Chemistry, 2024. Verfasst von Da-Jiang Zou und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, PR China. zhangchangjun@zjut.edu.cn. Hauptthemen laut MEDLINE: Monoamine Oxidase Inhibitors, Alzheimer Disease, Iron Chelating Agents, Deferiprone. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: National Basic Research Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A chromone–deferiprone compound 25c was created as a promising lead for AD therapy, which displayed h MAO-B inhibition (IC 50 = 1.58 μM), iron-chelating (pFe 3+ = 18.79), antioxidant, anti-ferroptosis, and improving the cognitive impairment abilities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Monoamine Oxidase InhibitorsAlzheimer DiseaseIron Chelating AgentsDeferiproneMonoamine OxidaseChromonesHumansStructure-Activity RelationshipAnimalsAntioxidantsFerroptosisMolecular StructureMolecular Docking SimulationBlood-Brain BarrierDose-Response Relationship, Drug

Substanzen

Monoamine Oxidase InhibitorsIron Chelating AgentsDeferiproneMonoamine OxidaseChromonesAntioxidants

Autor:innen und Institutionen

  • College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, PR China. zhangchangjun@zjut.edu.cn.
  • School of Ethnic-Minority Medicine, Guizhou Minzu University, Guiyang 50025, China.
  • Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceutical, Zhejiang University of Technology, Hangzhou, China.
  • Key Laboratory for Green Pharmaceutical Technologies and Related Equipment of Ministry of Education, Key Laboratory of Pharmaceutical Engineering of Zhejiang Province, Hangzhou, 310014, China. xyycz@zjut.edu.cn.

ORCID-Profile: Yuan-Yuan Xie

Förderung

  • National Basic Research Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Zou, D. J., Liu, R. Z., Lv, Y. J., Guo, J. N., Fan, M. L., Zhang, C. J., & Xie, Y. Y. (2024). Chromone–deferiprone hybrids as novel MAO-B inhibitors and iron chelators for the treatment of Alzheimer's disease. Organic & Biomolecular Chemistry. https://doi.org/10.1039/d4ob00919c

Vancouver

Zou DJ, Liu RZ, Lv YJ, Guo JN, Fan ML, Zhang CJ, et al. Chromone–deferiprone hybrids as novel MAO-B inhibitors and iron chelators for the treatment of Alzheimer's disease. Organic & Biomolecular Chemistry. 2024. doi:10.1039/d4ob00919c

BibTeX
@article{Zou2024,
  author = {Zou, Da-Jiang and Liu, Ren-Zheng and Lv, Yang-Jing and Guo, Jia-Nan and Fan, Miao-Liang and Zhang, Chang-Jun and Xie, Yuan-Yuan},
  title = {Chromone–deferiprone hybrids as novel MAO-B inhibitors and iron chelators for the treatment of Alzheimer's disease},
  journal = {Organic & Biomolecular Chemistry},
  year = {2024},
  doi = {10.1039/d4ob00919c}
}
Kostenlos starten →